Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 12/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9917866 | 0.83 | PRKCQ (0.55) | BRD4PRKCQNUDT1JAK2ROCK2 | |
| SCHEMBL9917753 | 0.82 | BRD4 (0.48) | BRD4PRKCQNUDT1JAK2ROCK2 | |
| SCHEMBL9917750 | 0.81 | BRD4 (0.47) | BRD4PRKCQNUDT1JAK2ROCK2 | |
| SCHEMBL9917764 | 0.80 | PRKCQ (0.68) | BRD4PRKCQNUDT1JAK2ROCK2 | |
| SCHEMBL9917725 | 0.75 | PRKCQ (0.72) | BRD4PRKCQNUDT1JAK2ROCK2 | |
| SCHEMBL2675408 | 0.75 | PRKCQ (0.72) | BRD4PRKCQNUDT1JAK2ROCK2 | |
| SCHEMBL9917919 | 0.75 | PRKCQ (0.46) | BRD4PRKCQNUDT1JAK2ROCK2 | |
| SCHEMBL9917722 | 0.74 | PRKCQ (0.74) | BRD4PRKCQNUDT1JAK2ROCK2 | |
| SCHEMBL9917858 | 0.73 | PRKCQ (0.80) | BRD4PRKCQNUDT1JAK2ROCK2 | |
| SCHEMBL28945566 | 0.70 | NUDT1 (0.56) | BRD4PRKCQNUDT1JAK2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367697-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367697-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120149680-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149680-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-14 | — | — | US | disclosed |
| US-8173635-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173635-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-08 | — | — | US | disclosed |
| US-20090291937-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-26 | — | — | US | disclosed |
| US-20090291937-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291937-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | BRD4 1026/4885PRKCQ 38/4885NUDT1 1351/4885 |
| US-20120149680-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | BRD4 1026/4885PRKCQ 38/4885NUDT1 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.